

1FCW

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/21 (08-03)
Approved for use through 08/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

| | | | |
|---|----------------------|------------------------|--------------|
| TRANSMITTAL FORM (to be used for all correspondence after initial filing) | Application Number | 10/731,690 | |
| | Filing Date | December 8, 2003 | |
| | First Named Inventor | Nurulain ZAVERI et al. | |
| | Art Unit | 1654 | |
| | Examiner Name | Unassigned | |
| Mail Stop | Amendment | Attorney Docket Number | 8500-0269.20 |

| ENCLOSURES (Check all that apply) | | |
|---|--|--|
| <input checked="" type="checkbox"/> No fee due <input type="checkbox"/> Fee Transmittal <input type="checkbox"/> Fee(s) due <input type="checkbox"/> Fee Transmittal <input type="checkbox"/> Check for \$* <input checked="" type="checkbox"/> Charge any underpayment or credit any overpayment to Deposit Account No. 18-0580 <input checked="" type="checkbox"/> Return postcard <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> 2 nd Supplemental Information Disclosure Statement & Form PTO-1449 <input checked="" type="checkbox"/> Copies of International Search Report and cited references <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts / Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s): | <input type="checkbox"/> After Allowance Communication to a Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below): |
| Remarks: | | |

| SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT | | | |
|--|--|-----------|-------------------|
| Firm or Individual Name (print/type) | Mark L. Warzel, Registration No. 47,264 Reed IP Law Group | Telephone | (650) 330-0900 |
| Signature | | Date | December 13, 2004 |

| CERTIFICATE OF TRANSMISSION/MAILING | | | |
|---|-----------|------|-------------------|
| I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. | | | |
| Name (print/type) | Joe Clark | | |
| Signature | | Date | December 13, 2004 |



Atty Dkt No. 8500-0269.20
SRI No. US-4649-3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Nurulain ZAVERI et al.

Confirmation No.: 3278

Serial No.: 10/731,690

Group Art Unit: 1654

Filing Date: December 8, 2003

Examiner: Unassigned

Title: ANALOGS OF GREEN TEA POLYPHENOLS AS CHEMOTHERAPEUTIC AND
CHEMOPREVENTIVE AGENTS

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This is a Second Supplemental Information Disclosure Statement submitted for the Examiner's consideration. Applicants respectfully request that the Examiner review and make of record the references identified below.

The references listed below were cited in an International (PCT) Search Report dated November 12, 2004, for the PCT application corresponding to the above-identified U.S. patent application. A copy of the Search Report, including an indication of the purported relevance of the cited references, is enclosed. Copies of the references are also enclosed.

A PTO-1449 form listing the references accompanies this paper. Applicants request that the Examiner kindly initial and return to them a copy of this form to indicate that the references have been reviewed and made of record. The references are as follows:

| NONPATENT DOCUMENTS |
|---|
| Chemical Abstracts Service database CAPLUS, AN 1969:36948, DN 70:36948, RN:802-38-0: CLARK-LEWIS (1968), "Flavan Derivatives. XXV. Mass Spectra of 3-Hydroxyflavanones, Flavan -3-ols, and Flavan-3,4-diols," Australian Journal of Chemistry 21(12):3025-3054 (abstract only). |
| LEE al. (1992), "Flavan-3-ol Gallates and Proanthocyanidins from Pithecellobium Lobatum," <i>Phytochemistry</i> 31(6):2117-2120. |
| WEINGES (1964), "The Occurrence of Catechins in Fruits," <i>Phytochemistry</i> 3:263-266. |
| ZHU et al. (2001), "Study of Tea Polyphenol as a Reversal Agent for Carcinoma Cell Lines' Multidrug Resistance (Study of TP as a MDR Reversal Agent," <i>Nuclear Medicine and Biology</i> 28:735-740. |


This Second Supplemental Information Disclosure Statement is not intended as a representation that additional information material to the examination of this application does not exist or that any of the above references constitutes prior art to the present application within the meaning of 35 USC § 102.

As this Second Supplemental Information Disclosure Statement is being filed within three months of the date of the International Search Report (i.e, November 12, 2004), no fee is required at this time. If, for any reason, a fee is found to be necessary, our Deposit Account No. 18-0580 may be charged therefor.


The undersigned hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement (37 CFR § 1.97(e)(1)).

Respectfully submitted,

By:


Mark L. Warzel
Registration No. 47,264

REED IP LAW GROUP
800 Menlo Avenue, Suite 210
Menlo Park, California 94025
(650) 330-0900 Telephone
(650) 330-0980 Facsimile

| | | | | | | |
|--|---|----|--|------------------------|--------------------------|--------------|
| Substitute for form 1449A/PTO | | |  | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | | Application Number | | 10/731,690 | |
| | | | Filing Date | | December 8, 2003 | |
| | | | First Named Inventor | | Nurulain ZAVERI et al. | |
| | | | Art Unit | | 1654 | |
| | | | Examiner Name | | Unassigned | |
| Sheet | 1 | of | 1 | Attorney Docket Number | | 8500-0269.20 |

| OTHER DOCUMENTS — NONPATENT LITERATURE DOCUMENTS | | | | |
|--|----------|---|---|--|
| Examiner Initials* | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), Title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T | |
| | AM | Chemical Abstracts Service database CAPLUS, AN 1969:36948, DN 70:36948, RN:802-38-0, CLARK-LEWIS (1968), "Flavan Derivatives. XXV. Mass Spectra of 3-Hydroxyflavanones, Flavan -3-ols, and Flavan-3,4-diols," Australian Journal of Chemistry 21(12):3025-3054 (abstract only). | * | |
| | AN | LEE al. (1992), "Flavan-3-ol Gallates and Proanthocyanidins from Pithecellobium Lobatum," <i>Phytochemistry</i> 31(6):2117-2120. | | |
| | AO | WEINGES (1964), "The Occurrence of Catechins in Fruits," <i>Phytochemistry</i> 3:263-266. | | |
| | AP | ZHU et al. (2001), "Study of Tea Polyphenol as a Reversal Agent for Carcinoma Cell Lines' Multidrug Resistance (Study of TP as a MDR Reversal Agent," <i>Nuclear Medicine and Biology</i> 28:735-740. | | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.